European Medicines Agency approves new indication for everolimus

Everolimus approved for the treatment of postmenopausal women with HR positive, HER2 negative advanced breast cancer without symptomatic visceral disease, in combination with exemestane, after recurrence or progression to a non-steroidal aromatase inhibitor. The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) adopted a new indication as follows: "Afinitor is indicated for the treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor". Read more here.